EA
SRPT icon

Emerald Advisers’s Sarepta Therapeutics SRPT Stock Holding History

Emerald Advisers’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-19,830
Closed -$1.27M – 267
2025
Q1 		$1.27M Buy
19,830
+6,588
+50% +$694K 0.06% 123
2024
Q4 		$1.61M Buy
13,242
+4,904
+59% +$601K 0.06% 122
2024
Q3 		$1.04M Buy
8,338
+4,059
+95% +$561K 0.04% 133
2024
Q2 		$676K Buy
4,279
+2,426
+131% +$312K 0.03% 156
2024
Q1 		$240K Buy
+1,853
New +$227K 0.01% 219
2023
Q4 		– Sell
-3,454
Closed -$419K – 252
2023
Q3 		$419K Sell
3,454
-72
-2% -$8.14K 0.02% 177
2023
Q2 		$404K Sell
3,526
-8,814
-71% -$1.14M 0.02% 178
2023
Q1 		$1.7M Sell
12,340
-3,448
-22% -$447K 0.08% 129
2022
Q4 		$2.05M Sell
15,788
-325
-2% -$37.7K 0.1% 119
2022
Q3 		$1.78M Buy
16,113
+12,369
+330% +$1.25M 0.09% 122
2022
Q2 		$281K Buy
+3,744
New +$275K 0.01% 199
2021
Q1 		– Sell
-10,670
Closed -$1.82M – 292
2020
Q4 		$1.82M Sell
10,670
-340
-3% -$50.4K 0.06% 135
2020
Q3 		$1.55M Buy
11,010
+371
+3% +$56.4K 0.06% 132
2020
Q2 		$1.71M Sell
10,639
-2,816
-21% -$383K 0.07% 129
2020
Q1 		$1.32M Sell
13,455
-144
-1% -$16.5K 0.08% 124
2019
Q4 		$1.75M Buy
13,599
+2,426
+22% +$245K 0.07% 126
2019
Q3 		$842K Buy
11,173
+1,100
+11% +$130K 0.04% 151
2019
Q2 		$1.53M Sell
10,073
-44,753
-82% -$5.44M 0.06% 127
2019
Q1 		$6.54M Sell
54,826
-21,607
-28% -$2.78M 0.27% 111
2018
Q4 		$8.34M Sell
76,433
-138,715
-64% -$17.3M 0.41% 85
2018
Q3 		$34.7M Sell
215,148
-84,196
-28% -$11.5M 1.28% 17
2018
Q2 		$39.6M Sell
299,344
-104,804
-26% -$9.88M 1.49% 10
2018
Q1 		$29.9M Sell
404,148
-482,831
-54% -$32.2M 1.2% 17
2017
Q4 		$49.4M Sell
886,979
-6,505
-0.7% -$345K 1.9% 2
2017
Q3 		$40.5M Buy
893,484
+18,077
+2% +$722K 1.65% 6
2017
Q2 		$29.5M Buy
875,407
+56,702
+7% +$1.85M 1.23% 21
2017
Q1 		$24.2M Buy
818,705
+270,134
+49% +$8.36M 1% 32
2016
Q4 		$15M Buy
548,571
+300,244
+121% +$12.1M 0.64% 67
2016
Q3 		$15.3M Buy
248,327
+12,821
+5% +$388K 0.68% 48
2016
Q2 		$4.49M Buy
+235,506
New +$4.36M 0.22% 131
2015
Q4 		– Sell
-362,891
Closed -$11.7M – 333
2015
Q3 		$11.7M Buy
362,891
+12,764
+4% +$433K 0.61% 55
2015
Q2 		$10.7M Buy
+350,127
New +$7.16M 0.51% 69
2014
Q4 		– Sell
-400,585
Closed -$8.45M – 355
2014
Q3 		$8.45M Buy
400,585
+32,957
+9% +$744K 0.5% 67
2014
Q2 		$11M Buy
367,628
+91,989
+33% +$2.91M 0.62% 51
2014
Q1 		$6.62M Sell
275,639
-173,298
-39% -$4.42M 0.37% 97
2013
Q4 		$9.14M Buy
448,937
+65,864
+17% +$1.96M 0.5% 68
2013
Q3 		$18.1M Sell
383,073
-38,548
-9% -$1.48M 1.02% 20
2013
Q2 		$16M Buy
+421,621
New +$15.1M 0.98% 22

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Emerald Advisers's SRPT Position: Q2 2025 in Review

Emerald Advisers sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 19,830 shares — an estimated $1.27M sold.

Emerald Advisers first reported a position in SRPT in Q2 2013 and held it in 38 quarters. The position peaked at $49.4M in Q4 2017. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

  • Emerald Advisers reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Emerald Advisers sold 19,830 Sarepta Therapeutics shares in Q2 2025, an estimated $1.27M.
  • Emerald Advisers first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 38 quarters.
  • Emerald Advisers's Sarepta Therapeutics position peaked at $49.4M in Q4 2017.
  • 362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on Emerald Advisers's 13F filing for Q2 2025, filed 4 Aug 2025.